## We Claim:

- 1. An immunogenic composition comprising:
- (1) a multivalent polysaccharide-protein conjugate mixture consisting of capsular polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F of *Streptococcus pneumoniae* conjugated to a carrier protein; and
  - (2) a pharmaceutically acceptable carrier.
  - 2. The immunogenic composition of claim 1, wherein the carrier protein is CRM<sub>197</sub>.
  - 3. The immunogenic composition of claim 1, further comprising an adjuvant.
- 4. The immunogenic composition claim 3, wherein the adjuvant is an aluminum-based adjuvant.
- 5. The immunogenic composition of claim 4, wherein the adjuvant is selected from the group consisting of aluminum phosphate, aluminum sulfate and aluminum hydroxide.
- 6. The immunogenic composition of claim 5, wherein the adjuvant is aluminum phosphate.
- 7. The immunogenic composition of claim 1 formulated as single 0.5 mL dose containing 2 µg of each saccharide, except for 6B at 4 µg; about 32 µg CRM<sub>197</sub> carrier protein; 0.125 mg of elemental aluminum (0.5 mg aluminum phosphate) adjuvant; 150 mM sodium chloride and 20 mM L-histidine buffer.
- 7. 8. A method of inducing an immune response to a *Streptococcus pneumoniae* capsular polysaccharide, comprising administering to a human an immunologically effective amount of the immunogenic composition of claim 1.
- 8. 9. The method of claim 7 8, wherein the immunogenic composition administered is a single 0.5 mL dose formulated to contain: 2  $\mu$ g of each saccharide, except for 6B at 4  $\mu$ g; about 32  $\mu$ g CRM<sub>197</sub> carrier protein; 0.125 mg of elemental aluminum (0.5 mg aluminum phosphate) adjuvant; 150 mM sodium chloride and 20 mM L-histidine buffer.